GRI Bio (NASDAQ: GRI) has reported encouraging 6-week interim biomarker data from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The study, which has completed enrollment of approximately 35 subjects, showed that GRI-0621 treated patients demonstrated favorable reduction in fibrogenesis biomarkers and increased basement membrane remodeling.
The Independent Data Monitoring Committee (IDMC) has recommended continuing the study as planned, noting no safety concerns in the data reviewed. The trial remains blinded, with patients randomized in a 2:1 ratio for GRI-0621 4.5mg or placebo. The company expects to report topline results in Q3 2025, with additional pulmonary function test data expected in the coming weeks.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.